KR20230114747A - Her2 표적화제 - Google Patents

Her2 표적화제 Download PDF

Info

Publication number
KR20230114747A
KR20230114747A KR1020237017469A KR20237017469A KR20230114747A KR 20230114747 A KR20230114747 A KR 20230114747A KR 1020237017469 A KR1020237017469 A KR 1020237017469A KR 20237017469 A KR20237017469 A KR 20237017469A KR 20230114747 A KR20230114747 A KR 20230114747A
Authority
KR
South Korea
Prior art keywords
antibody
amino acid
seq
acid sequence
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237017469A
Other languages
English (en)
Korean (ko)
Inventor
유키나리 카토
미카 카네코
다이스케 나카야마
마사유키 쿠로기
Original Assignee
오노 야꾸힝 고교 가부시키가이샤
고쿠리츠다이가쿠호진 도호쿠다이가쿠
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 오노 야꾸힝 고교 가부시키가이샤, 고쿠리츠다이가쿠호진 도호쿠다이가쿠 filed Critical 오노 야꾸힝 고교 가부시키가이샤
Publication of KR20230114747A publication Critical patent/KR20230114747A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020237017469A 2020-11-30 2021-11-29 Her2 표적화제 Pending KR20230114747A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JPJP-P-2020-198044 2020-11-30
JP2020198044 2020-11-30
JP2021110912 2021-07-02
JPJP-P-2021-110912 2021-07-02
PCT/JP2021/043538 WO2022114163A1 (ja) 2020-11-30 2021-11-29 Ｈｅｒ２標的化剤

Publications (1)

Publication Number Publication Date
KR20230114747A true KR20230114747A (ko) 2023-08-01

Family

ID=81754499

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237017469A Pending KR20230114747A (ko) 2020-11-30 2021-11-29 Her2 표적화제

Country Status (10)

Country Link
US (2) US20240002531A1 (https=)
EP (1) EP4253420A4 (https=)
JP (2) JP7393774B2 (https=)
KR (1) KR20230114747A (https=)
AU (1) AU2021387127A1 (https=)
CA (1) CA3199473A1 (https=)
IL (1) IL303154A (https=)
MX (1) MX2023005864A (https=)
TW (2) TW202546008A (https=)
WO (1) WO2022114163A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3247010A1 (en) 2022-04-08 2023-10-12 Ono Pharmaceutical Co., Ltd. CHIMERIC ANTIGEN RECEPTOR FOR TUMOR TARGETING
EP4504914A4 (en) * 2022-04-08 2026-04-29 Fate Therapeutics Inc Cells having solid tumor targeting backbone and use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2639222T5 (es) 2000-10-06 2023-11-24 Kyowa Kirin Co Ltd Células que producen unas composiciones de anticuerpo
PT2330131E (pt) 2009-12-07 2015-01-14 Fundació Privada Institució Catalana De Recerca I Estudis Avancats Anticorpos contra a variante truncada de her-2 ctf-611
US9243057B2 (en) * 2010-08-31 2016-01-26 The Regents Of The University Of California Antibodies for botulinum neurotoxins
US11851479B2 (en) * 2018-06-18 2023-12-26 Dxdiscovery, Inc. Methods and compositions for pertussis diagnosis
CA3247010A1 (en) * 2022-04-08 2023-10-12 Ono Pharmaceutical Co., Ltd. CHIMERIC ANTIGEN RECEPTOR FOR TUMOR TARGETING

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Kaneko et al., 2020, Biochem. Biophys. Rep., 24: 100826
Kato and Kaneko, 2014, Sci. Rep., 4: 5924
Yamada et al., 2017, Monoclon. Antib. Immunodiagn. Immunother., 36(2): 72

Also Published As

Publication number Publication date
IL303154A (en) 2023-07-01
MX2023005864A (es) 2023-06-05
EP4253420A1 (en) 2023-10-04
TW202546008A (zh) 2025-12-01
WO2022114163A1 (ja) 2022-06-02
US11981747B1 (en) 2024-05-14
US20240002531A1 (en) 2024-01-04
TW202229359A (zh) 2022-08-01
JP7393774B2 (ja) 2023-12-07
AU2021387127A1 (en) 2023-06-22
JP2024020436A (ja) 2024-02-14
JPWO2022114163A1 (https=) 2022-06-02
CA3199473A1 (en) 2022-06-02
EP4253420A4 (en) 2024-11-06

Similar Documents

Publication Publication Date Title
CN113347994B (zh) 使用her3抗原结合分子治疗和预防癌症
CN113227135B (zh) 用于治疗癌症和其他疾病的对紧密连接蛋白18.2具有特异性的结合分子、其组合物和方法
US11891445B1 (en) Anti-B7-H3 antibody and use thereof
KR101854443B1 (ko) 항-her2 항체 및 이의 접합체
KR102159773B1 (ko) 글리피칸-3에 대한 고친화력 단클론 항체 및 이의 용도
TWI551296B (zh) 反應b7-h3之抗體、其免疫活性片段及使用
KR20200139725A (ko) Her3 항원 결합 분자
KR102029248B1 (ko) 암세포 특이적 항체, 항암제 및 암 검사 방법
RS56219B1 (sr) Antitela protiv csf-1r
KR20110039475A (ko) 암의 치료 및 예방용 의약 조성물
JP7324777B2 (ja) 腫瘍抗原に対するｌ２ａ５抗体またはその機能的断片
US20230365676A1 (en) Cd33 antibodies
CN115505043A (zh) 特异性结合糖基化ceacam5的抗体
JP2024020436A (ja) Ｈｅｒ２標的化剤
KR102249981B1 (ko) 단클론성 항-gpc-1 항체 및 이의 용도
CN116472350A (zh) 新型抗cldn18抗体
KR20230030626A (ko) 루이스 y에 대한 인간화된 항체
CN116615239A (zh) Her2靶向剂
HK40091222A (zh) Her2靶向剂
CN114907478A (zh) 结合lag-3的抗体及其用途
WO2023222068A1 (en) Anti-cd200r1 antibodies
CN111704668B (zh) 抗ccr4抗体及其在治疗癌症中的应用
CN121464158A (zh) 抗Claudin18.2抗体及其制备和使用方法
EP4493595A1 (en) Antibodies against lypd3
WO2025132836A1 (en) Antibodies against cd24

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230523

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20241011

Comment text: Request for Examination of Application